]>
IRCT20210426051090N1 IRCT 2021-06-12 Shahre-kord University of Medical Sciences The effect of atorvastatin on Covid 19 The effect of atorvastatin on on inflammatory factors and prognosis outcomes in patients with Covid 19, hospitalized in Hajar Hospital, Shahrekord University of Medical Sciences, 2021 2021-06-22 anticipated 80 Complete https://irct.ir/trial/56387 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization of patients will be done by the responsible researcher using Excel software. Randomization will be done by creating blocks. Blocks will be considered in variable sizes including 4 or 6 or 8 patients. In order to randomly assign patients in the two groups receiving medication and placebo, a specific code including 2 letters and a number will be assigned to each patient. This code will be unique to each patient (for example, code AB1 for patient number one). Only the researcher in charge of the study will know that each code is assigned to the drug or placebo group, Blinding description: The drugs required for the participants in the study will be fully covered at the research site will be available to the participants in the study. Study participants and evaluators of the final outcome of patients will not be aware of the drug or placebo. 3 Covid-19. Intervention 1: Control group: Patients receiving standard diet treatment (according to national protocol) + placebo. Intervention 2: Intervention group: Patients with standard diet treatment + atorvastatin 40 mg made by Mehr Daroo Pharmaceutical Company daily for 14 days. Yes - There is a plan to make this available What will be shared: Only part of the data such as information about the main outcome or the like can be shared. When: 2021-2022 To whom: En The data will be available only to researchers working in academic and scientific institutions Conditions: I have not decided yet Where to obtain: I have not decided yet How to obtain: I have not decided yet Comments:
public Shahab Moghaddam
Parastar aven
Sahrekord Iran (Islamic Republic of) 8816754633 +98 38 3222 0016 st-moghaddam.sh@skums.ac.ir Shahre-kord University of Medical Sciences scientific Shahab Moghaddam
Parastar Aven
Shahrekord Iran (Islamic Republic of) 8816754633 +98 38 3222 0016 st-moghaddam.sh@skums.ac.ir Shahre-kord University of Medical Sciences Iran (Islamic Republic of) Patients with confirmed molecular test of blood oxygen saturation level SpO2 less than 90% in room air Patients with pulmonary involvement in radiological studies Do not take statins The patient is not in a state of shock and sepsis 18 years no limit Both Having advanced heart disease (CHF) Liver disease (based on primary LFT) Incidence of statin side effects Long-term use of corticosteroids to die Pulmonary underlying disease B34.2 Coronavirus infection, unspecified Treatment - Drugs Treatment - Drugs Control group: Patients receiving standard diet treatment (according to national protocol) + placebo. Intervention group: Patients with standard diet treatment + atorvastatin 40 mg made by Mehr Daroo Pharmaceutical Company daily for 14 days O2 Saturation. Timepoint: 1 and 7 days after the start of the study. Method of measurement: Pulse oximetry device. FBS. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test. IL-6. Timepoint: 1 and 14 days after the start of the study. Method of measurement: blood test. Alt، Ast ،Alkp ، Bill total ، Bill direct. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test. BUN, Na, K, Cr. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test. PT, PTT, INR. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test. TG, Total Cholesterol, LDL, HDL. Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test. CBC(diff). Timepoint: 1 and 7 days after the start of the study. Method of measurement: blood test. LDH. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test. ESR. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test. CRP. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test. Ferritin. Timepoint: 1 and 7 and 14 days after the start of the study. Method of measurement: blood test. Shahre-kord University of Medical Sciences Approved 2021-05-12 Shahre-kord University of Medical Sciences Parastar Aven Shahrekord Chahar-Mahal-va-Bakhtiari Iran (Islamic Republic of)